Replies to post #177924 on Cytodyn Inc (CYDY)

[Hookmeistr]

Thanks Daemon57.

For anyone wondering where the relevant information concerning leronlimab is within this document, go to page 13 and read under the emerging treatments section.

Here's the excerpt:

Other potential treatments are molecules that
suppress the intense inflammatory response seen in
covid-19. Leronlimab is a monoclonal antibody that
blocks the function of CCL-5. It has been shown to
be effective and safe in HIV213 and reduces plasma
interleukin-6 levels in covid-19.214 Clinical trials
are ongoing to evaluate the efficacy of leronlimab
post-covid-19 (NCT04343651, NCT04347239,
NCT04678830).

Here are the referenced resource materials:

213

Dhody K, Pourhassan N, Kazempour K, et al. PRO 140, a monoclonal
antibody targeting CCR5, as a long-acting, single-agent maintenance
therapy for HIV-1 infection. HIV Clin Trials 2018;19:85-93. doi:10.10
80/15284336.2018.1452842

214

Patterson BK, Seethamraju H, Dhody K, et al. CCR5 inhibition in
critical COVID-19 patients decreases inflammatory cytokines,
increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma
by day 14. Int J Infect Dis 2021;103:25-32. doi:10.1016/j.
ijid.2020.10.101